秘鲁利马一线药物敏感结核分枝杆菌分离株的氟喹诺酮类药物敏感性。
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru.
机构信息
Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martín de Porres, 15102, Lima, Peru.
Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
出版信息
BMC Res Notes. 2021 Nov 14;14(1):413. doi: 10.1186/s13104-021-05832-0.
OBJECTIVE
To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs.
RESULTS
There were 279 M. tuberculosis isolates from the two cohorts (2004-2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0-0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0-0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.
目的
在两个不同时间点确定对氟喹诺酮类药物（FQs）代表性药物氧氟沙星（OFX）的耐药率，这些结核分枝杆菌分离株对一线药物敏感。
结果
从两个队列中共有 279 株结核分枝杆菌分离株（2004-2005 年：238 株；2017 年：41 株）进行了 OFX 药物敏感性测试（临界浓度：2μg/ml）。在队列 1 的 238 株分离株中，未检测到对 OFX 的耐药性（95%CI 0-0.016）；同样，在队列 2 的 41 株分离株中，也未检测到对 OFX 的耐药性（95%CI 0-0.086）。我们的研究结果表明，在秘鲁，氟喹诺酮类药物仍然是治疗一线药物敏感结核病的可行选择。
Zotero 插件